Moderna Stock Is Trending Today: What the New Cancer Vaccine Means for the Pharma Giant
Moderna stock fell after Phase 3 results showed its personalized cancer vaccine reduced melanoma recurrence risk by 42%. Learn what the data mean for MRNA and its oncology plans.
by Scott Matherson//6 minute read








